TRPV4 ANTAGONISTS

A combination comprising a compound of Formula (I): or a pharmaceutically acceptable salt thereof; and one or more other therapeutic agents, selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotension II receptor antagonists, va...

Full description

Saved in:
Bibliographic Details
Main Authors PATTERSON, JACLYN, R, EIDAM, HILARY, SCHENCK, HILFIKER, MARK, A, BROOKS, CARL, CHEUNG, MUI, STOY, PATRICK, YE, GUOSEN, HOANG, TRAM, H, GOODMAN, KRISTA, B, HAMMOND, MARLYS
Format Patent
LanguageEnglish
French
German
Published 06.04.2016
Subjects
Online AccessGet full text

Cover

Loading…
Abstract A combination comprising a compound of Formula (I): or a pharmaceutically acceptable salt thereof; and one or more other therapeutic agents, selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotension II receptor antagonists, vasopeptidase inhibitors, vasopressin receptor modulators, diuretics, digoxin, beta blocker, aldosterone antagonists, iontropes, NSAIDS, nitric oxide donors, calcium channel modulators, muscarinic antagonists, steroidal anti-inflammatory drugs, bronchodilators, anti-histamines, leukotriene antagonist, HMG-CoA reductase inhibitors, dual non-selective ²-adrenoceptor and ± 1 -adrenoceptor antagonists, type-5 phosphodiesterase inhibitors, and renin inhibitors.
AbstractList A combination comprising a compound of Formula (I): or a pharmaceutically acceptable salt thereof; and one or more other therapeutic agents, selected from the group consisting of endothelin receptor antagonists, angiotensin converting enzyme (ACE) inhibitors, angiotension II receptor antagonists, vasopeptidase inhibitors, vasopressin receptor modulators, diuretics, digoxin, beta blocker, aldosterone antagonists, iontropes, NSAIDS, nitric oxide donors, calcium channel modulators, muscarinic antagonists, steroidal anti-inflammatory drugs, bronchodilators, anti-histamines, leukotriene antagonist, HMG-CoA reductase inhibitors, dual non-selective ²-adrenoceptor and ± 1 -adrenoceptor antagonists, type-5 phosphodiesterase inhibitors, and renin inhibitors.
Author HAMMOND, MARLYS
HILFIKER, MARK, A
HOANG, TRAM, H
GOODMAN, KRISTA, B
EIDAM, HILARY, SCHENCK
YE, GUOSEN
CHEUNG, MUI
STOY, PATRICK
BROOKS, CARL
PATTERSON, JACLYN, R
Author_xml – fullname: PATTERSON, JACLYN, R
– fullname: EIDAM, HILARY, SCHENCK
– fullname: HILFIKER, MARK, A
– fullname: BROOKS, CARL
– fullname: CHEUNG, MUI
– fullname: STOY, PATRICK
– fullname: YE, GUOSEN
– fullname: HOANG, TRAM, H
– fullname: GOODMAN, KRISTA, B
– fullname: HAMMOND, MARLYS
BookMark eNrjYmDJy89L5WQQDAkKCDNRcPQLcXT39_MMDgnmYWBNS8wpTuWF0twMCm6uIc4euqkF-fGpxQWJyal5qSXxrgFG5kaGBoZmTobGRCgBAK8FHzE
ContentType Patent
DBID EVB
DatabaseName esp@cenet
DatabaseTitleList
Database_xml – sequence: 1
  dbid: EVB
  name: esp@cenet
  url: http://worldwide.espacenet.com/singleLineSearch?locale=en_EP
  sourceTypes: Open Access Repository
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Chemistry
Sciences
DocumentTitleAlternate ANTAGONISTES DE TRPV4
TRPV4-ANTAGONISTEN
ExternalDocumentID EP2721016B1
GroupedDBID EVB
ID FETCH-epo_espacenet_EP2721016B13
IEDL.DBID EVB
IngestDate Fri Jul 19 15:57:19 EDT 2024
IsOpenAccess true
IsPeerReviewed false
IsScholarly false
Language English
French
German
LinkModel DirectLink
MergedId FETCHMERGED-epo_espacenet_EP2721016B13
Notes Application Number: EP20120814591
OpenAccessLink https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20160406&DB=EPODOC&CC=EP&NR=2721016B1
ParticipantIDs epo_espacenet_EP2721016B1
PublicationCentury 2000
PublicationDate 20160406
PublicationDateYYYYMMDD 2016-04-06
PublicationDate_xml – month: 04
  year: 2016
  text: 20160406
  day: 06
PublicationDecade 2010
PublicationYear 2016
RelatedCompanies GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
RelatedCompanies_xml – name: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
Score 3.0278175
Snippet A combination comprising a compound of Formula (I): or a pharmaceutically acceptable salt thereof; and one or more other therapeutic agents, selected from the...
SourceID epo
SourceType Open Access Repository
SubjectTerms CHEMISTRY
HETEROCYCLIC COMPOUNDS
METALLURGY
ORGANIC CHEMISTRY
Title TRPV4 ANTAGONISTS
URI https://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20160406&DB=EPODOC&locale=&CC=EP&NR=2721016B1
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwY2BQMQFWusCOhQlor5OlrklqqoFuoolxiq5hchow_ZhYmKSlgGZ0ff3MPEJNvCJMI5gYMmF7YcDnhJaDD0cE5qhkYH4vAZfXBYhBLBfw2spi_aRMoFC-vVuIrYsatHdsaAZMk2ZqLk62rgH-Lv7Oas7OQJaaX5CtEdBBQGknYEeJFdiKNgdlBtcwJ9CmlALkGsVNkIEtAGhYXokQA1NqnjADpzPs4jVhBg5f6Hw3kAnNesUiDIIhQQFhJgqOfiGO7v5-nsEhwaIMCm6uIc4eukCz4-H-iHcNgLvCWIyBBdi9T5VgUDA3NzZPM0hKNkw2SDMxTEtOTDJItTQ3NU9JAzalzFITJRkkcRojhUdOmoELFCDgVSZmMgwsJUWlqbLACrQkSQ7sdQBsdnFr
link.rule.ids 230,309,783,888,25576,76876
linkProvider European Patent Office
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfR3LTsMwzJoGYtzGADGePaDeKlqaNexQofVFB-tDW5h2q_pIpF22iRXx-7hVN7jAzUoky7Hs2I4fAbgnaHQxsCBVr9NQIZyrSkr0QtFygfJDnogoqoxuEBr-O3ldDBYtWO56Yeo5oV_1cETUqBz1vazv683PI5ZT11ZuH7IlLq2fPWY6chMdawbKpCE7lunGkRPZsm0jJIdT8xEJwm0LA6UD9LBppQzu3KqaUja_LYrXhcMYka3KE2jxVQ869u7jtR4cBU2-G8FG9ban0GXTeE6kUchGL1E4nrHZGUiey2xfQdzJ_hyJG--p0M-hjeE9vwCJUp0KNcu1XBVEE3maqXxIB7QQ6EoZPO1D_080l__s3UHHZ8EkmYzDtys4rphTV5wY19AuPz75DRrTMrut2fAN6AJ0Xg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Apatent&rft.title=TRPV4+ANTAGONISTS&rft.inventor=PATTERSON%2C+JACLYN%2C+R&rft.inventor=EIDAM%2C+HILARY%2C+SCHENCK&rft.inventor=HILFIKER%2C+MARK%2C+A&rft.inventor=BROOKS%2C+CARL&rft.inventor=CHEUNG%2C+MUI&rft.inventor=STOY%2C+PATRICK&rft.inventor=YE%2C+GUOSEN&rft.inventor=HOANG%2C+TRAM%2C+H&rft.inventor=GOODMAN%2C+KRISTA%2C+B&rft.inventor=HAMMOND%2C+MARLYS&rft.date=2016-04-06&rft.externalDBID=B1&rft.externalDocID=EP2721016B1